High-purity isotype control antibodies designed specifically to validate assays, establish baselines, and accelerate VHH therapeutics discovery.
In the rapidly evolving landscape of biopharmaceuticals, single-domain antibodies (sdAbs)—commonly referred to as nanobodies or VHH domains—have emerged as one of the most promising therapeutic modalities. Derived originally from the heavy-chain-only antibodies (HCAbs) found naturally in camelids (llamas, alpacas, camels), VHH molecules possess unique structural advantages. They are exceptionally small (~15 kDa, which is approximately one-tenth the size of a standard IgG antibody), highly stable under extreme temperature and pH conditions, and possess an elongated complementary-determining region 3 (CDR3) loop that can bind to cryptic, hard-to-reach active sites on target proteins.
Over the past decade, the biotechnology sector has transitioned from viewing nanobodies as research novelties to integrating them as core pillars of therapeutic pipelines. The landmark regulatory approval of Caplacizumab (Cablivi) by the FDA and EMA for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) proved the clinical and commercial viability of VHH-based drugs. Today, the global nanobody market is expanding exponentially, driven by investments in oncology, autoimmune disorders, neurology, and infectious diseases.
Industrially, the demand for high-throughput VHH humanization has skyrocketed. Large pharmaceutical companies and agile biotech startups alike require robust humanization platforms that minimize clinical attrition rates. Modern drug pipelines frequently utilize humanized VHH domains in multi-specific antibody formats, antibody-drug conjugates (ADCs), and as targeting domains for chimeric antigen receptor (CAR) T-cell and NK-cell therapies.
The application scenarios of humanized VHH are diverse, addressing several long-standing challenges of traditional monoclonal antibodies (mAbs):
Successful VHH humanization requires a delicate balance. The standard protocol involves grafting the camelid CDR loops onto a human VH3 framework scaffold. However, simple CDR grafting often leads to a significant loss of affinity or structural stability because camelid framework residues contribute to the spatial positioning of the CDR loops.
To overcome this, structural modeling and back-mutation strategies are employed. Critical "hallmark" residues in the camelid framework (specifically at positions 37, 44, 45, and 47, which govern the hydrophobicity and solubility of the VHH domain) must be carefully assessed. Retaining certain camelid residues (back-mutations) or utilizing modern in silico computational tools and AI-driven deep learning algorithms allows designers to predict structural compatibility, ensuring the humanized variants retain high solubility, thermal stability, and picomolar affinity.
Alpha Lifetech Inc. was founded by a group of scientists with extensive experience in membrane protein production, nanobody discovery, monoclonal development, and other pharmaceutical pre-development services. Based on our several technology service platforms, Alpha Lifetech Inc. has launched nearly 10,000 high-quality spot membrane protein reagents, cytokines, drug target antibodies and other related reagents.
Whether you're working in the fields of immunology, cell biology, molecular biology, or any other scientific discipline, Alpha Lifetech's comprehensive range of research products will help you achieve accurate and reliable results. We pride ourselves on being able to offer a comprehensive set of high-quality products and services tailored to customer needs, which help advance the projects of scientific research institutions, academics, and enterprises in the life science industry.
Alpha Lifetech Inc. is committed to providing the highest level of customer services, competitive pricing, speedy delivery, and a comprehensive, cutting-edge product offering. Our sales and technical support staff are available to help you select the right products and service solutions.
As a reliable supplier and partner, Alpha Lifetech Inc. always puts customers first. We cherish every opportunity to collaborate with worldwide customers in scientific exploration. Welcome to contact our technical support at any time.
Our years of manufacturing experience and refined products provide you with better protection.
Through tailored products, adaptable service and packaging choices, and unwavering support, Alpha Lifetech Inc. guarantees that researchers have access to the most fitting and efficient tools tailored to their research endeavors.
Our team of experienced scientists works closely with customers to design and execute tailored strategies for nanobody discovery, ensuring the generation of high-quality leads that align with project goals.
Antibody humanization from a broad range of parental species including mouse, rat, rabbit, llama, and avian.
Our Membrane Proteomics platform offers a comprehensive solution for the identification, quantification, and characterization of membrane proteins, providing valuable insights into their functions.
Alpha Lifetech can offer the native antibody libraries (scFv, Fab, VHH Formats and customized) from host animals like Goat, Camel and Llama.
Alpha Lifetech Inc. provides a wide range of technology platforms, including membrane protein, antibody discovery, single B cell sorting, and hybridoma technology. In the dynamic landscape of scientific research, access to dependable and top-tier tools is paramount for obtaining consistent and accurate outcomes.
Our platform utilizes phage and yeast display technology to develop different forms of antibodies: VHH single domain antibodies, Fab antibodies, and scFv antibodies, resulting in high affinity and high specificity antibodies.
Read More
The aptamer platform provided by Alpha Lifetech includes two categories: aptamer synthesis platform, which mainly involves SELEX aptamer library synthesis service and aptamer development service, and aptamer screening platform including screening services based on SELEX technology for proteins, peptides, cells, small molecules, and other target molecules, as well as aptamer optimization and identification analysis services.
Read More
Our monoclonal antibody development services include three technologies: phage display technology, single-B cell technology, and hybridoma cell technology, which produce monoclonal antibodies for different species.
Read More
We also provide a series of technical services related to antibody engineering, stable cell line construction, yeast display, protein interaction analysis, etc., laying the foundation for antibody development.
Read MoreHear from our partners and clients worldwide who trust us for their nanobody discovery and development needs.
Select from our comprehensive list of scientific services below to accelerate your therapeutic pipelines from discovery through humanization.
Comprehensive VHH screening and selection services using immunized or synthetic camelid libraries.
Screening and optimization of antigen-binding fragments (Fab) for targeted therapies.
Single-chain variable fragment (scFv) construction and screening for multi-specific applications.
State-of-the-art phage display platforms for high-throughput screening of massive antibody libraries.
High-efficiency sorting of single B cells to isolate native, high-affinity therapeutic antibodies.
Classic, reliable hybridoma development for robust monoclonal antibody generation across species.
Advanced molecular evolution and affinity maturation platform using phage display methodologies.
High-quality yeast display library construction for screening membrane proteins and soluble antigens.
To ensure complete project support, we offer the following specialized service modules for research and industrial pipelines.
Custom-built immune, naive, or synthetic phage display libraries with high diversity.
High-throughput biopanning against complex targets, including whole cells and membrane proteins.
Chemical synthesis and modifications of high-affinity DNA or RNA aptamers.
SELEX-based screening for proteins, peptides, cells, and small molecules.
Sequence truncation and chemical modifications to enhance in vivo stability and affinity.
Characterization of binding kinetics, thermodynamic parameters, and structural validation.
Custom target exploration using next-generation sequencing (NGS) and bioinformatic analysis.
High-throughput mouse monoclonal antibody discovery via hybridoma or B cell sorting platforms.
Generation of rabbit monoclonal antibodies known for high affinity and epitope diversity.
Development of high-yield CHO or HEK293 stable cell lines for robust protein/antibody expression.
Optimized immunization protocols for llamas, alpacas, rabbits, and rodents.
Affinity and kinetics characterization using Biacore (SPR) and Octet (BLI) technologies.
FACS-based screening of yeast libraries to isolate target-specific binders with high stability.